Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer

New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Volkmar, Wöckel, Achim, Lux, Michael P., Janni, Wolfgang, Hartkopf, Andreas D., Nabieva, Naiba, Taran, Florin-Andrei, Hadji, Peyman, Tesch, Hans, Ettl, Johannes, Lüftner, Diana, Welslau, Manfred, Belleville, Erik, Brucker, Sara Y., Schütz, Florian, Fasching, Peter A., Fehm, Tanja N., Kolberg, Hans-Christian, Schneeweiss, Andreas, Overkamp, Friedrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255740/
https://www.ncbi.nlm.nih.gov/pubmed/30498279
http://dx.doi.org/10.1055/a-0715-2899
_version_ 1783374006615801856
author Müller, Volkmar
Wöckel, Achim
Lux, Michael P.
Janni, Wolfgang
Hartkopf, Andreas D.
Nabieva, Naiba
Taran, Florin-Andrei
Hadji, Peyman
Tesch, Hans
Ettl, Johannes
Lüftner, Diana
Welslau, Manfred
Belleville, Erik
Brucker, Sara Y.
Schütz, Florian
Fasching, Peter A.
Fehm, Tanja N.
Kolberg, Hans-Christian
Schneeweiss, Andreas
Overkamp, Friedrich
author_facet Müller, Volkmar
Wöckel, Achim
Lux, Michael P.
Janni, Wolfgang
Hartkopf, Andreas D.
Nabieva, Naiba
Taran, Florin-Andrei
Hadji, Peyman
Tesch, Hans
Ettl, Johannes
Lüftner, Diana
Welslau, Manfred
Belleville, Erik
Brucker, Sara Y.
Schütz, Florian
Fasching, Peter A.
Fehm, Tanja N.
Kolberg, Hans-Christian
Schneeweiss, Andreas
Overkamp, Friedrich
author_sort Müller, Volkmar
collection PubMed
description New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class of substances (palbociclib, ribociclib and abemaciclib). Further pathways under investigation are PI3K and AKT signalling pathways along with diverse approaches to their inhibition. Initial study results were also presented recently on both mechanisms of action. Insights into the PARP inhibitors, moreover, are increasing; studies in this respect are also examining in which population they can be used most effectively. This review offers a summary of the recent studies and an outline of the latest developments.
format Online
Article
Text
id pubmed-6255740
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-62557402018-11-27 Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer Müller, Volkmar Wöckel, Achim Lux, Michael P. Janni, Wolfgang Hartkopf, Andreas D. Nabieva, Naiba Taran, Florin-Andrei Hadji, Peyman Tesch, Hans Ettl, Johannes Lüftner, Diana Welslau, Manfred Belleville, Erik Brucker, Sara Y. Schütz, Florian Fasching, Peter A. Fehm, Tanja N. Kolberg, Hans-Christian Schneeweiss, Andreas Overkamp, Friedrich Geburtshilfe Frauenheilkd New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class of substances (palbociclib, ribociclib and abemaciclib). Further pathways under investigation are PI3K and AKT signalling pathways along with diverse approaches to their inhibition. Initial study results were also presented recently on both mechanisms of action. Insights into the PARP inhibitors, moreover, are increasing; studies in this respect are also examining in which population they can be used most effectively. This review offers a summary of the recent studies and an outline of the latest developments. Georg Thieme Verlag KG 2018-11 2018-11-26 /pmc/articles/PMC6255740/ /pubmed/30498279 http://dx.doi.org/10.1055/a-0715-2899 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Müller, Volkmar
Wöckel, Achim
Lux, Michael P.
Janni, Wolfgang
Hartkopf, Andreas D.
Nabieva, Naiba
Taran, Florin-Andrei
Hadji, Peyman
Tesch, Hans
Ettl, Johannes
Lüftner, Diana
Welslau, Manfred
Belleville, Erik
Brucker, Sara Y.
Schütz, Florian
Fasching, Peter A.
Fehm, Tanja N.
Kolberg, Hans-Christian
Schneeweiss, Andreas
Overkamp, Friedrich
Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
title Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
title_full Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
title_fullStr Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
title_full_unstemmed Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
title_short Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
title_sort update breast cancer 2018 (part 4) – genomics, individualized medicine and immune therapies – in the middle of a new era: treatment strategies for advanced breast cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255740/
https://www.ncbi.nlm.nih.gov/pubmed/30498279
http://dx.doi.org/10.1055/a-0715-2899
work_keys_str_mv AT mullervolkmar updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT wockelachim updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT luxmichaelp updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT janniwolfgang updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT hartkopfandreasd updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT nabievanaiba updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT taranflorinandrei updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT hadjipeyman updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT teschhans updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT ettljohannes updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT luftnerdiana updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT welslaumanfred updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT bellevilleerik updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT bruckersaray updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT schutzflorian updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT faschingpetera updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT fehmtanjan updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT kolberghanschristian updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT schneeweissandreas updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer
AT overkampfriedrich updatebreastcancer2018part4genomicsindividualizedmedicineandimmunetherapiesinthemiddleofaneweratreatmentstrategiesforadvancedbreastcancer

Ejemplares similares